A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis
Copyright © 2024 Elsevier Ltd. All rights reserved..
No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors independent of histopathology provide mechanistic insight into causation and influence prognosis and treatment of pituitary adenomas. We propose a new approach to guide prognosis and therapy of pituitary adenomas by integrating clinical, genetic, biochemical, radiological, pathological, and molecular information for all adenomas arising from anterior pituitary cell lineages. The system uses an evidence-based scoring of risk factors to yield a cumulative score that reflects disease severity and can be used at the bedside to guide pituitary adenoma management. Once validated in prospective studies, this simple manageable classification system could provide a standardised platform for assessing disease severity, prognosis, and effects of therapy on pituitary adenomas.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
The lancet. Diabetes & endocrinology - 12(2024), 3 vom: 30. Feb., Seite 209-214 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ho, Ken K Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 26.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/S2213-8587(23)00382-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367910489 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367910489 | ||
| 003 | DE-627 | ||
| 005 | 20240229155058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2213-8587(23)00382-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM367910489 | ||
| 035 | |a (NLM)38301678 | ||
| 035 | |a (PII)S2213-8587(23)00382-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ho, Ken K Y |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors independent of histopathology provide mechanistic insight into causation and influence prognosis and treatment of pituitary adenomas. We propose a new approach to guide prognosis and therapy of pituitary adenomas by integrating clinical, genetic, biochemical, radiological, pathological, and molecular information for all adenomas arising from anterior pituitary cell lineages. The system uses an evidence-based scoring of risk factors to yield a cumulative score that reflects disease severity and can be used at the bedside to guide pituitary adenoma management. Once validated in prospective studies, this simple manageable classification system could provide a standardised platform for assessing disease severity, prognosis, and effects of therapy on pituitary adenomas | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Fleseriu, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Wass, John |e verfasserin |4 aut | |
| 700 | 1 | |a Katznelson, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Raverot, Gerald |e verfasserin |4 aut | |
| 700 | 1 | |a Little, Andrew S |e verfasserin |4 aut | |
| 700 | 1 | |a Castaño, Justo P |e verfasserin |4 aut | |
| 700 | 1 | |a Reincke, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes, M Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Kaiser, Ursula B |e verfasserin |4 aut | |
| 700 | 1 | |a Chanson, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Gadelha, Mônica |e verfasserin |4 aut | |
| 700 | 1 | |a Melmed, Shlomo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Diabetes & endocrinology |d 2013 |g 12(2024), 3 vom: 30. Feb., Seite 209-214 |w (DE-627)NLM233773398 |x 2213-8595 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:3 |g day:30 |g month:02 |g pages:209-214 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2213-8587(23)00382-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2024 |e 3 |b 30 |c 02 |h 209-214 | ||